Rational design of small molecule inhibitors targeting the Ras GEF, SOS1

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Ras GTPases are crucial for cell proliferation, and their aberrant signaling drives human cancers.
• Guanine nucleotide exchange factors (GEFs), such as SOS1, activate Ras by catalyzing guanine nucleotide exchange.
• SOS1 is a key transducer of receptor tyrosine kinase signaling to the Ras pathway.

Purpose of the Study:

• To identify and characterize small-molecule inhibitors targeting the catalytic site of SOS1 and its downstream Ras activity.
• To establish a proof of principle for the rational design of inhibitors targeting Ras GEF enzymatic activity.

Main Methods:

• Employed a rational drug design approach combining virtual and experimental screening.
• Utilized mutagenesis and structure-activity relationship studies to map the inhibitor's binding site.
• Assessed inhibitor efficacy in biochemical assays, cell signaling, and cell proliferation studies.

Main Results:

• Identified lead inhibitor NSC-658497 that binds to the SOS1 catalytic site.
• NSC-658497 competitively inhibits SOS1-Ras interaction and SOS1 GEF activity.
• Demonstrated dose-dependent inhibition of Ras signaling, downstream pathways, and cancer cell proliferation by NSC-658497.

Conclusions:

• Established a validated strategy for the rational design of small-molecule inhibitors against Ras GEFs.
• NSC-658497 represents a promising therapeutic lead for targeting Ras-driven cancers.
• Targeting SOS1 enzymatic activity offers a viable approach to inhibit oncogenic Ras signaling.